Delisle M.J., Schvartz C. 131 iodine and differentiated thyroid cancers. // Ann Endocrinol (Paris); 1996 57(3):186-93
Dietlein M., Moka D., Scheidhauer K., et al. Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests. // Nucl Med Commun; 2000 21(11):991-1000
Dottorini M.E., Vignati A., Mazzucchelli L., et al. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. // J Nucl Med; 1997 38(5):669-75
Driedger A.A., Kidane H.G., Pewe J.E. Impact of I-131 uptake on ablation of post surgical remnants.// International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.68
Falesi M., Signore A., Ventroni G., et al. Role initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyriod carcinoma metastases. // J Nucl Med; 1998 39(9):1542-6
Farahari J., Parlowsky T., Mader U., et al. Differentiated thyroid cancer in children and adolescents. // Langenbecks Arch Surg; 1998 383(3):235 — 239.
Farina G.P., Pisano M., Baccoli A., et al. Therapeutic strategies in differentiated cancer of the thyroid: total thyroidectomy. // G Chir; 2000 21(11-12):469-74
Goslings B.M., Pelikan H.L., Lion J. Resalts of I-131 treatment in advanced stages of differentiated thyroid carcinoma (DTC). // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.61
Grant C.S. Operattive and postoperative manegement of the patient with follicular and Hurthler cell carcinoma: Do they differ- // Surg. Clin. North Am. –1995.-Vol.75,№3. – P.395-403.
Grigsby P. Cost minimization analysis and utility of pretreatment and posttreatment total body ioidine-131 scans in patients with thyriod carcinoma. // Cancer; 1998 82(5):931-5
Grunwald F., Menzel C., Bender H., et al. Redifferentation therapy — induced radioiodine uptake in thyriod cancer. // J Nucl Med; 1998 39(11):1903-6
Gulzar Z., Jana S., Young I., et al. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer. // Endocr Pract; 2001 7(4):244-9
Haigh P.I., Ituarte P.H., Wu H.S., et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. // Cancer; 2001 91(12):2335-42
Hall P., Mattsson A., Boice J.D. Thyroid cancer after diagnostic administration of iodine-131. // Radiat Res; 1996 145(1):86 — 92.
Hermanska J., Karny M., Zimak J., et al. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma. // J Nucl Med; 2001 42(7):1084-90
Hodgson D.C., Brierley J.D., Tsang R.W., Panzarella T. Prescribing 131Iodine based on neck uptake produces effective thyriod ablation and reduced hospital stay. // Radiother Oncol; 1998 47(3):325-30
Hurley J.R. Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients. // Endocr Pract; 2000 6(5):401-6
Ikekubo K. Hino M., Ito H., et al. The early detection of metastases differentiated thyriod cancer using 131-I total body scan and treatment with 131I. // Kaku Igaku; 1991 28(3):247-59
Jochansen K, Woodhoyse N.J., Odugbesan O. Comparison of 1073 and 3700 MBq MBq iodini-131 in postoperative ablation of residual thyriod tissue in patients with differentiated thyriod cancer. // J Nucl Med; 1991 32(2):352-4
Kao C.H, Yen T,C. Stunning effects after a diagnostic dose of iodine-131. // Nuklearmedizin; 1998 37(1):30-2
Kasagi K., Miyamoto S., Endo K., et al. Increased uptake of ioidine-131 in metastases od differentiated thyriod carcinoma associated with less severe hypothyroidism following total thyroidectomy. // Cancer; 1993 72(6):1983-90
Khan J.H., McElhinney D.B., Rahman S,B., et al. Pulmonary metastases of endocrine origin: the role of surgery. // Chest; 1998 114(2):526-34
Kim J.H., Kim E.S., Lee J.V. Radiation dosimetry of in vivo and in vitro irradiation of iodine-131. // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.82
Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. // J Clin Endocrinol Metab; 2001 86(7):3430-5
Koerber C., Schmutzler C., Rendl J., et al. Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. // Clin Nucl Med 1999 24(11):849-851
Koong S.S., Reynjlds J.C., Movius E.D., et al. Lithyum as a potentional adjuvant to 131I therapy of metastatic well differentiated thyriod carcinoma. // J Clin Endocrinol Met; 1999 84(3):912-6
Krausz Y. Nuclear endocrinology as a monitoring tool. // Semin Nucl Med; 2001 31(3):238-50
Krishnamurthy G.T., Blahd W.H. Radioiodine I-131 therapy in the management of thyriod cance. A prospective study. // Cancer; 1977 40(1):195-202
Kuriakose M.A., Hicks W.L., Loree T.R., et al. Risk group-based management of differentiated thyroid carcinoma. // J R Coll Surg Edinb; 2001 46(4):216-23
Ladenson P.W., Ewertz M.E., Dickey R.A. Practical application of recombinant thyrotropin testing in clinical practice. // Endocr Pract; 2001 7(3):195-201
Leger A.F. Distant metastasis of differentiated thyroid cancers. Diagnosis by 131 iodine (I 131) and treatment. // Ann Endocrinol (Paris); 1995 56(3):205-8
Leger F.A., Izembart M., Dagousset F., et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyriod remnants in differentiated thyriod carcinoma. // Eur J Nucl Med 1998 25(3):242-6
Lerch H., Schober O., Kuwert T., Saur H.B. Survival of differentiated thyriod carcinoma studiedin 500 patients. // J Clin Oncol; 1997 15(5):2067-75
Leung S.F., Law M.W., Ho S.K. Efficacy of low-dose iodine-131 ablation of post-operative thyriod remnants: a study of 69 cases. // Br J Radiol 1992 65(778):905-9
Lin J.D., Chao T.C., Huang M.J., et al. Use of radioactive iodine for thyriod remnant ablation in well-differentiated thyriod carcinoma to replace thyriod reoperation. // Am J Clin Oncol; 1998 21(1):77-81
Lin J.D., Kao P.F., Chao T.C. The effect of radioactive iodine in thyriod remnant ablation and treatment of well differentiated thyriod carcinoma. // Br J Radiol; 1998 71(843):307-13
Lin W.Y., Shen Y.Y., Wang S.J. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. // Clin Nucl Med, 1996 21(10):780-2
Lind P. 131I whole body scintigraphy in thyriod cancer patients. // Q J Nucl Med; 1999 43(3):188-94
Lippi F., Capezzone M., Angelini F., et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. // Eur J Endocrinol; 2001 144(1):5-11
Logue J.P.,Tsang R.W., Brierley J.D., Simpson W.J. Radioiodine ablation of residual tissue in thyriod cancer: relationship between administered activity, neck uptake and outcome. // Br J Radiol; 1994 67(803):1127-31
Makarewicz L., Mikosinski S, Karwowoska A. at al. Comparision of test and therapeutic activity kinetics of 131J. // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.63
Mandel S.J., Shankar L.K., Benard F., et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. // Clin Nucl Med; 2001 26(1):6-9
Matsushita T., Toyota S., Katoh N., Nakagawa T. Iodine-131 treatment of thyriod cance: relation between effective half-life and efficacy of treatment. // Radiat Med; 1994 12(4):167-70
Maxon H.P., Thomas S.R., Hertzberg V.S., et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyriod cancer. // New Eng J Med; 1983 309:937
Maxon H.R. The role of radioiodine in the treatment of childhood thyroid cancer – A dosimetric approach. // In: NIH proceedings of a workshop, September 10-11, 1992, p. 109-116.
Mazzaferri E.L. Thyroid remnant ablation in the treatment of differentiated thyroid carcinoma. // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.77
Mazzaferri E.L., Young R.L. Papillary thyroid carcinoma: A 10-year follow-up report of the impact of therapy in 576 patients. // Am J Med; 1981 70(3):511-18.
McDougall I.R. 131I treatment of 131I negative whole-body scan, and positive thyroglobulin in differentiated thyriod carcinoma: what is being treated? // Thyriod; 1997 7(4):669-72
McDougall I.R. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. // Clin Nucl Med; 1995 20(10):869-75
Melliere D., Berrahal D., Hindie E., et al. Surveillance after treatment of differentiated thyroid cancers. // Ann Chir; 2000 125(9):856-60
Menzel C., Grunwald F., Schomburg A., et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. // J Nucl Med; 1996 37(9):1496-503
Miyamoto S., Kasagi K., Endo K., et al. Resalts of radioiodine therapy in 47 patients with distant metastases of differentiated thyriod carcinoma. // Nippon Igaku Hoshasen Gakkai Zasshi; 1991 51(7):810-21
M'Kacher R., Schlumberger M., Lregal J.D, et al. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. // J Nucl Med; 1998 39(5):825-9
Morris L.F., Waxman A.D., Braunstein G.D. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. // J Clin Endocrinol Metab; 2001 86(8):3507-11
Muratet J.P. Giraud P., Daver А., et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyriod carcinoma. // J Nucl Med; 1997 38(9):1362-8
Muratet J.P., Daver А., Minier J.F., Larra F. Influence of scanning dose of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyriod carcinoma. // J Nucl Med 1998; 39(9):1546-50
North D.L., Shearer D.R., Hennessey J.V., Donovan G.L. Effective half-life of 131I in thyroid cancer patients. // Health Phys; 2001 81(3):325-9
O`Connel M.E., Flover M,A,, Hinton P,J., et al. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyriod carcinoma using quantitive scanning and PET. // Radiother Oncol; 1993 28(1):16-26
O`Doherty M.J., Coakley A.J. Drug therapy alternatives in the treatment of thyriod cancer. // Drugs; 1998 55(6):801-12
Ozaki O., Ito K., Manabe Y., et al. Clinical study on pulmonary metastases of differentiated thyriod carcinoma — with special reference to the extent of thyriod resection and RI therapy. // Nippon Geka Gakkai Zasshi; 1985 86(12):1596-9
Paloyan E., Walker R.P., Lawrence A.M. Guidelines for the use of radioiodine, thyriod hormone, and treatment of metastatic disease in patients with differentiated thyriod cancer. // Surg Oncol Clin N Am; 1998 7(4):665-80
Paryani S.B., Chobe R.J., Scott W., et al. Manegement of thyroid carcinoma with radioactive 131I. // J Radiat Oncol Biol Phys; 1996 36(1):83-6
Pelican D.M., Lion H.L., Hermans J., Goslings B.M. The role of radioactive iodine in the treatment of advanced differentiated thyriod carcinoma. // Clin Endocrinol (Oxf); 1997 47(6):713-20
Petrich T., Borner A.R., Weckesser E., et al. Follow-up of differentiated thyroid cancer patients using rhTSH — preliminary results. // Nuklearmedizin; 2001 40(1):7-14
Pichon M.F., Basuyau J.P., Gory-Delabaere G., et al. Standards, options and recommendations for blood tumor markers in thyroid cancers. // Bull Cancer; 2001 88(8):775-92
Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan [see comments]. // J Clin Endocrinol Metab; 1995 80(5):1488-92
Ramanna L., Waxman A.D., Brachman M.B., et al. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyriod cancer patients. // Clin Nuck Med; 1985 10(11):791-5
Reynolds J.C. How much uptake is enough to treat? Are post therapy scans worhwhile? // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.81
Reynolds J.C., Comparison of I-131 absorbed radiation doses in children and adalts: a tool for estimating therapeutic I-131 doses in children. // In: NIH proceedings of a workshop, September 10-11, 1992, p. 125-133.
Reynolds J.C., Robbins J. The changing role of radioiodine in the management of differentiated thyriod cancer. // Semin Nucl Med; 1997 27(2):152-64
Ronga G., Fiorentino A., Paserio E., et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in post-surgical follow-up of differentiated thyriod carcinoma. // J Nucl Med; 1990 31(11):1766-71
Rosler H., Birrer A., Luscher D., Kinser J. Long-term course in differentiated thyroid gland carcinoma. // Schweiz Med Wochenschr; 1992 122(48):1843-57
Salvatori M., Rufini V., Garganese M.C., Di Giuda D. Radioiodine therapy in differentiated thyroid carcinoma. // Rays; 2000 25(2):221-38
Samaan N.A., Schultz P.N., Haynie T.P., Ordonez N.G. Pulmonary metastases of differentiated thyriod carcinoma: treatment results in 101 patients. // J Clin Endocrinol Metab; 1985 60(2):376-80
Samaan, N.A., Schultz P.N. Hickey R.C. et al. The result of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective rewiew of 1599 patients. // J Clin Endocrin Metabol; 1992 75(3):714-720
Samuel A.M., Rajashekharrao B., Shah D.H. Pulmonary metastases in children and adolescents with well-differentiated thyriod cancer. // J Nucl Med; 1998 39(9):1531-6
Sanders L.E., Cady B. Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. // Arch. Surg. – 1998.-Vol.133.№4.-P.419-425.
Santora J., Nemec J., Kubinyi J. Therapy of thyroid carcinoma using radioiodine. // Cas Lek Cesk; 2001 140(7):217-9
Sarkar S.D., Afriyie M.O., Palestro C.J. Recombinant human thyroid-stimulating hormone-aided scintigraphy: comparison of imaging at multiple times after I-131 administration. // Clin Nucl Med; 2001 26(5):392-5
Schicha H., Dietlein M. Radioiodine therapy in differetiated thyroid gland carcinoma. Zentralbl Chir; 1997 122(4):266-73
Schlumberger M. I 131 therapy for elevated thyroglobulin levels. // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.77
Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive Iodine Treatment and External Radiotherapy for Lung and Bone Metastases from Thyroid Carcinoma. // J Nucl Med; 1996 37(4):598-605
Schlumberger M., Pacini F. Thyroid tumors. // Editions Nucleon, Paris, 1999 317pp.
Schlumberger M.J., Torlantano M. Papillary and follicular thyroid carcinoma. // Baillieres Best Pract Res Clin Endocrinol Metab; 2000 14(4):601-13
Schmutzler C. Regulation of the sodium/iodide symporter by retinoids--a review.review. Exp Clin Endocrinol Diabetes. 2001;109(1):41-4. Review.
Shyh-Ing Guan, Wei-Jen Chang, Ming-Yang Yeh, Wei-Lian Chen. The effect of I-131 radionuclide therapy for carcinoma of thyroid on natural killer cell activity. // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.79
Siddiqi A., Foley R.R., Britton K.E., et al. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. // Clin Endocrinol (Oxf); 2001 55(4):515-21
Simon D., Koehrle J, Reiners C., et al. Redifferentation therapy with retinoids: therapeutic option for advanced follicular and papillary thyriod carcinoma. // World Surg; 1998 22(6):569-74
Sisson J., Jamader D., Kazerooni T. at al. 131-I treatment of micronodular lung metastases from papillary thyroid cancer: are the tumor too small? // International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.82
Sisson J.C., Giordano T.J., Jamadar D.A., et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. // Cancer; 1996 78(10):2184-92
Smanik P.A., Cho J-C, Jhiang S.M. Cloning of human sodium/iodine transportet and mechanism of the loss radioiodine uptake activity in thyroid tumors.// International symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.80
Solans R., Bosch J.A., Galofre P., et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. // J Nucl Med; 2001 42(5):738-43
Sykes A.J., Gattamaneni H.R. Carcinoma of the thyriod in children: a 25-year experience. // Med Pediatr Oncol; 1997 29(2):103-7
Tatar F.A., Morita E., Ituarte P.H., et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients. // World J Surg; 2001 25(6):718-22
Travagli J.P., Cailleux A.F., Ricard M, et al. Combination of radioiodine (I-131) and probe-guided surgery for persistent or recurrent thyroid carcinoma. // J Clinl Endocrinol Metab; 1998 83(8):2675-80
Tsahg R.W., Brierley J.D., Simpson W.J., et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyriod carcinoma. // Cancer; 1998 82(2):375-88
van Wyngaarden M., McDougall I.R. What the role of 1100 MBq (<30mCi) radioiodine 131I in the treatment of patients with differentiated thyriod cancer? // Nucl Med Commun; 1996 17(3):199-207
Vermiglio F., Violi M.A., Finocchiaro M.D., et al. Short-term effectiveness
8-09-2015, 20:23